Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

5HZ1 Analyst Ratings

Currently, no data available

Based on NaN analysts giving stock ratings to

Hangzhou

Tigermed Consulting Co., Ltd. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

5HZ1 Stock 12 Month Forecast

There Are No Analyst Ratings for DE:5HZ1 In The Last 3 Months.

Highest Price Target―

Average Price Target―

Lowest Price Target―

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

5HZ1 Financial Forecast

5HZ1 Earnings Forecast

Next quarter’s earnings estimate for 5HZ1 is €0.03 with a range of >-€0.01 to €0.07. The previous quarter’s EPS was €0.09. 5HZ1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 5HZ1 has Performed in-line its overall industry.

5HZ1 Sales Forecast

Next quarter’s sales forecast for 5HZ1 is €222.13M with a range of €204.83M to €239.43M. The previous quarter’s sales results were €209.85M. 5HZ1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 5HZ1 has Performed in-line its overall industry.

Detailed List of Analyst Forecasts

Chris Pan

Goldman Sachs

€6.73→€6.87

Buy

20.55%

Upside

Reiterated

11/21/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Clinigence Holdings (NASDAQ: NUTX), CSPC Pharmaceutical Group (Other OTC: CHJTF) and Hangzhou Tigermed Consulting Co., Ltd. Class H (Frankfurt: DE:5HZ1)

Linda Shu

HSBC

€5.54→€5.85

Buy

2.67%

Upside

Reiterated

11/05/25

HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Michael Luo CFA

CLSA

€6.38→€5.65

Buy

-0.94%

Downside

Reiterated

10/30/25

Yang Huang

J.P. Morgan

€4.01→€4.12

Sell

-27.75%

Downside

Reiterated

10/29/25

J.P. Morgan Sticks to Their Sell Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

UBS

Not Ranked

UBS

€6.19

Buy

8.57%

Upside

Reiterated

10/28/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

€5.53

Buy

-3.03%

Downside

Reiterated

09/01/25

David Li

Bank of America Securities

€6.07

Buy

6.48%

Upside

Reiterated

08/29/25

Unknown Analyst

CICC

Not Ranked

CICC

€6.23

Buy

9.33%

Upside

Reiterated

08/29/25

Ruili Bian

Citi

€4.01→€7.91

Buy

38.80%

Upside

Reiterated

07/14/25

Citi Reaffirms Their Buy Rating on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

€5.42

Buy

-4.93%

Downside

Reiterated

07/04/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

€4.12

Sell

-27.75%

Downside

Reiterated

06/12/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chris Pan

Goldman Sachs

€6.73→€6.87

Buy

20.55%

Upside

Reiterated

11/21/25

Linda Shu

HSBC

€5.54→€5.85

Buy

2.67%

Upside

Reiterated

11/05/25

HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Michael Luo CFA

CLSA

€6.38→€5.65

Buy

-0.94%

Downside

Reiterated

10/30/25

Yang Huang

J.P. Morgan

€4.01→€4.12

Sell

-27.75%

Downside

Reiterated

10/29/25

J.P. Morgan Sticks to Their Sell Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

UBS

Not Ranked

UBS

€6.19

Buy

8.57%

Upside

Reiterated

10/28/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

€5.53

Buy

-3.03%

Downside

Reiterated

09/01/25

David Li

Bank of America Securities

€6.07

Buy

6.48%

Upside

Reiterated

08/29/25

Unknown Analyst

CICC

Not Ranked

CICC

€6.23

Buy

9.33%

Upside

Reiterated

08/29/25

Ruili Bian

Citi

€4.01→€7.91

Buy

38.80%

Upside

Reiterated

07/14/25

Citi Reaffirms Their Buy Rating on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

€5.42

Buy

-4.93%

Downside

Reiterated

07/04/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

€4.12

Sell

-27.75%

Downside

Reiterated

06/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hangzhou Tigermed Consulting Co., Ltd. Class H

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+27.50%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +27.50% per trade.

1 Year

David LiBank of America Securities

Success Rate

2/2 ratings generated profit

Average Return

+22.30%

reiterated a buy rating 6 months ago

Copying David Li's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.30% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+22.30%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +22.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5HZ1 Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 5HZ1 has received 7 Buy Ratings, 39 Hold Ratings, and 1 Sell Ratings. 5HZ1 average Analyst price target in the past 3 months is ―.

Each month's total comprises the sum of three months' worth of ratings.

5HZ1 Stock Forecast FAQ

What is DE:5HZ1’s average 12-month price target, according to analysts?

Currently, no data Available

What is DE:5HZ1’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:5HZ1, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hangzhou Tigermed Consulting Co., Ltd. Class H a Buy, Sell or Hold?

Currently, no data Available

What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s share price target?

Currently, no data Available

What do analysts say about Hangzhou Tigermed Consulting Co., Ltd. Class H?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of Hangzhou Tigermed Consulting Co., Ltd. Class H?

To buy shares of DE:5HZ1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Stock Forecast & Price Target

5HZ1 Analyst Ratings

5HZ1 Stock 12 Month Forecast

5HZ1 Financial Forecast

5HZ1 Earnings Forecast

5HZ1 Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering Hangzhou Tigermed Consulting Co., Ltd. Class H

5HZ1 Analyst Recommendation Trends

5HZ1 Stock Forecast FAQ

Detailed List of Analyst Forecasts